Back to top

Analyst Blog

Anacor Pharmaceuticals, Inc. (ANAC - Snapshot Report) enrolled the first patient in a phase III study on its atopic dermatitis candidate, AN2728, for the topical treatment of mild-to-moderate atopic dermatitis.

The phase III trials comprise two multi-center, double-blind, randomized (2:1), placebo-controlled studies enrolling roughly 750 patients (two years and above) each.

An Investigator Static Global Assessment (ISGA) is a 5-point scale from 0 (clear) to 4 (severe). An ISGA score of 2 or 3 represents mild-to-moderate atopic dermatitis. The primary endpoint is to achieve an ISGA score of 0 or 1 with at least a 2-grade improvement from baseline on Day 29. Secondary endpoints include achieving an ISGA score of 0 or 1 at Day 29 along with the time to treatment success.

A long-term safety study will also be conducted by Anacor to evaluate the safety of intermittent use of AN2728 for a period of 12 months. Patients who complete either of the two phase III studies may enroll in this study.

We note that Anacor expects a response regarding its most advanced candidate Kerydin for the treatment of onychomycosis to be out by Jul 29, 2014. Anacor intends to launch Kerydin in the second half of 2014 assuming U.S. Food and Drug Administration approval.

Anacor carries a Zacks Rank #3 (Hold). We are encouraged by the pipeline progress at Anacor. However, the atopic dermatitis market is crowded with drugs like Elidel and Protopic. We also note that Sanofi (SNY - Analyst Report) and Regeneron Pharmaceuticals, Inc. (REGN - Analyst Report) are evaluating dupilumab for treating patients suffering from moderate-to-severe atopic dermatitis.

Investors looking for better-ranked stocks may consider a Zacks Rank #1 (Strong Buy) company like Shire (SHPG - Analyst Report).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SUPER MICRO… SMCI 27.00 +10.25%
CANADIAN SO… CSIQ 38.34 +8.18%
CENTURY ALU… CENX 26.97 +7.97%
WILLDAN GRO… WLDN 11.38 +5.86%
AROTECH COR… ARTX 3.78 +5.59%